Recent findings of improvements in hepatic steatosis and alcohol-inducedinflammation after inhibition of PCSK9 suggest PCSK9 inhibitors will become anovel therapeutic target for non-alcoholic fatty liver disease and alcoholicliver disease, both of which are the main reasons for cirrhosis [23, 24].Additionally, animal experiments discovered that inhibition of PCSK9 couldpromote LDL-R expression, thus protecting cirrhosis rats from intestinal originendotoxemia, a common complication in decompensate cirrhosis that results in highmortality [88]. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.